natgillin/translations-raw huggingface dataset:
Co-administration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug- drug interaction studies (see section 4.5).
Istodobna primjena asenapina s poznatim inhibitorima, induktorima ili supstratima tih metaboličkih putova ispitana je u nizu ispitivanja interakcija između lijekova (vidjeti dio 4.5).
Co-administration of atazanavir/ritonavir and Atripla is not recommended.
Ne preporučuje se istovremena primjena atazanavira/ritonavira s Atriplom.
Co-administration of atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir which
Istovremena primjena kombinacije atazanavir/ritonavir s boceprevirom rezultirala je manjom izloženošću
Co-administration of atorvastatin and
Istodobna primjena atorvastatina s
Co-administration of atorvastatin with Genvoya is not recommended.
Ne preporučuje se istodobna primjena atorvastatina i lijeka Genvoya.
Co-administration of atorvastatin with REYATAZ is not recommended.
Ne preporučuje se istovremena primjena atorvastatina s lijekom REYATAZ.
Co-administration of atorvastatin with Stribild is not recommended.
Ne preporučuje se istovremena primjena atorvastatina i Stribilda.
Co-administration of atorvastatin with Tybost is not recommended.
Ne preporučuje se istovremena primjena atorvastatina s lijekom Tybost.
Co-administration of Atripla and didanosine is not recommended (see section 4.4).
Ne preporučuje se istovremena primjena Atriple i didanozina (vidjeti dio 4.4).
Co-administration of Atripla and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil fumarate that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Ne preporučuje se istovremena primjena Atriple i didanozina jer se izloženost didanozinu značajno povećava u slučaju istovremene primjene tenofovirdizoproksilfumarata, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and Hypericum perforatum [St. John’s wort]) may decrease axitinib plasma concentrations.
Istodobna primjena aksitiniba sa snažnim induktorima CYP3A4/5 (npr. rifampicinom, deksametazonom, fenitoinom, karbamazepinom, rifabutinom, rifapentinom, fenobarbitalom i Hypericum perforatum [gospinom travom]) može smanjiti koncentracije aksitiniba u plazmi.
Co-administration of bedaquiline and moderate or strong CYP3A4 inducers used systemically should, therefore, be avoided (see section 4.5).
Istovremena primjena bedakilina i umjerenih ili snažnih CYP3A4 induktora primijenjenih sistemski, stoga se mora izbjegavati (vidjeti dio 4.5).
Co-administration of boceprevir and EVOTAZ is not recommended.
Ne preporučuje se istodobna
Co-administration of boceprevir with Aptivus/ritonavir is not recommended.
Istodobna primjena boceprevira s Aptivusom/ritonavirom se ne preporučuje.
Co-administration of boceprevir with medicines that induce or inhibit CYP3A4/5 could
Istodobna primjena boceprevira s lijekovima koji induciraju ili inhibiraju CYP3A4/5 može povećati ili smanjiti izloženost.
Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with oral sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC.
Istodobna primjena bosentana (umjerenog induktora CYP3A4, CYP2C9, a možda i CYP2C19) u dozi od 125 mg dva puta na dan sa sildenafilom u peroralnoj dozi od 80 mg tri puta na dan (u stanju dinamičke ravnoteže) tijekom 6 dana u zdravih dobrovoljaca rezultirala je smanjenjem AUC-a sildenafila od 63%.
Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC.
Istodobna primjena bosentana (umjerenog induktora CYP3A4, CYP2C9, a možda i CYP2C19) u dozi od 125 mg dva puta na dan sa sildenafilom u dozi od 80 mg tri puta na dan (u stanju dinamičke ravnoteže) tijekom 6 dana u zdravih dobrovoljaca rezultirala je smanjenjem AUC-a sildenafila od 63%.
Co-administration of bosentan and Aptivus with low dose ritonavir is not recommended (see section 4.4).
Istodobna primjena bosentana i Aptivusa s niskom dozom ritonavira se ne preporučuje. (vidjeti dio 4.4)
Co-administration of bosentan with cobicistat may lead to decreased cobicistat plasma concentrations.
Istovremena primjena bosentana s kobicistatom može uzrokovati smanjenje koncentracija kobicistata u plazmi.
Co-administration of Brimica Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Istodobna primjena Brimica Genuaira s drugim lijekovima koji sadrže antikolinergike i/ili dugodjelujuće β2 -adrenergičke agoniste nije ispitana i ne preporučuje se.
Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme including certain antidepressants (SSRIs and many tricyclic antidepressants, e.g. desipramine, imipramine, paroxetine), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medicinal product.
Istodobnoj primjeni bupropiona s lijekovima koji se metaboliziraju putem CYP2D6 izoenzima uključujući određene antidepresive (selektivne inhibitore ponovne pohrane serotonina i mnoge tricikličke antidepresive, npr. dezipramin, imipramin, paroksetin), antipsihotike (npr. haloperidol, risperidon i tioridazin), beta blokatore (npr. metoprolol) i antiaritmike tipa 1C (npr. propafenon i flekainid), treba pristupiti s oprezom i treba ih započeti u nižim dozama raspona doze lijeka koji se daje istodobno.
Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istodobna primjena karbamazepina, induktora P-gp-a, smanjuje koncentracije tenofoviralafenamida u plazmi, što moţe dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of carbamazepine, a potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istovremena primjena karbamazepina, snažnog induktora CYP3A, može značajno smanjiti koncentracije kobicistata i elvitegravira u plazmi, što može dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of carbamazepine, a potent CYP3A inducer, may significantly decrease cobicistat plasma concentrations.
Istovremena primjena karbamazepina, potentnog induktora enzima CYP3A, može značajno smanjiti koncentracije kobicistata u plazmi.
Co-administration of ceritinib with CYP3A substrates known to have narrow therapeutic indices (e.g. astemizole, cisapride, ciclosporin, ergotamine, fentanyl, pimozide, quinidine, tacrolimus, alfentanil and sirolimus) and CYP2C9 substrates known to have narrow therapeutic indices (e.g. phenytoin and warfarin) should be avoided.
Istodobnu primjenu ceritiniba s CYP3A supstratima za koje je poznato da imaju uske terapijske indekse (npr. astemizol, cisaprid, ciklosporin, ergotamin, fentanil, pimozid, kinidin, takrolimus, alfentanil i sirolimus) te CYP2C9 supstratima za koje se zna da imaju uske terapijske indekse (npr. fenitoin i varfarin) treba izbjegavati.
Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide.
Očekuje se da će istodobna primjena ciklosporina, jakog inhibitora P-gp-a, povisiti koncentracije tenofoviralafenamida u plazmi.
Co-administration of colesevelam and metformin extended-release (ER) tablets increases the exposure of metformin.
Istodobna primjena kolesevelama i tableta metformina s produženim oslobađanjem povećava izloženost metformina.
Co-administration of CRESEMBA with medicinal products which are substrates of OCT2 may result in increased plasma concentrations of these medicinal products.
Istodobna primjena lijeka CRESEMBA s lijekovima koji su supstrati za OCT2 moţe rezultirati povećanim koncentracijama ovih lijekova u plazmi.
Co-administration of CRESEMBA with medicinal products which are substrates of UGT may result in mildly increased plasma concentrations of these medicinal products.
Istodobna primjena lijeka CRESEMBA s lijekovima koji su supstrati za UGT moţe rezultirati blagim povećanjem koncentracija ovih lijekova u plazmi.
Co-administration of CRESEMBA with potent CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John‟s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine, is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see section 4.3).
Istodobna primjena lijeka CRESEMBA sa snaţnim induktorima CYP3A4/5 poput rifampicina, rifabutina, karbamazepina, barbiturata s dugotrajnim djelovanjem (npr. fenobarbital), fenitoina i gospine trave ili s umjerenim induktorima CYP3A4/5, poput efavirenza, nafcilina i etravirina je kontraindicirana jer ti lijekovi mogu značajno smanjiti koncentracije izavukonazola u plazmi (vidjeti dio 4.3).
Co-administration of CRESEMBA with the strong CYP3A4/5 inhibitor ketoconazole is contraindicated, since this medicinal product can significantly increase plasma concentrations of isavuconazole (see sections 4.3 and 4.5).
Istodobna primjena lijeka CRESEMBA sa snaţnim inhibitorom CYP3A4/5 ketokonazolom je kontraindicirana, jer taj lijek moţe značajno povećati koncentracije izavukonazola u plazmi (vidjeti dijelove 4.3 i 4.5).
Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.
Istodobna primjena darunavira i ritonavira s lijekovima koji se primarno metaboliziraju putem CYP2C9 (poput varfarina) te CYP2C19 (poput metadona), može rezultirati smanjenjem sistemske izloženosti tim lijekovima, što može smanjiti ili skratiti njihov terapijski učinak.
Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Istodobna primjena darunavira i ritonavira s lijekovima koji se primarno metaboliziraju putem CYP3A i/ili CYP2D6 ili prenose putem P-gp-a može rezultirati povećanom sistemskom izloženošću tim lijekovima, što može povećati ili produljiti njihov terapijski učinak i nuspojave.
Co-administration of darunavir and ritonavir and medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Istodobna primjena darunavira i ritonavira s lijekovima koji se primarno metaboliziraju putem CYP2D6 (poput flekainida, propafenona, metoprolola) može rezultirati povišenjem plazmatskih koncentracija tih lijekova, što može povećati ili produljiti njihov terapijski učinak i nuspojave.
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, systemic azoles like ketoconazole and clotrimazole).
Istodobna primjena darunavira i ritonavira i drugih lijekova koji inhibiraju CYP3A može smanjiti klirens darunavira i ritonavira te može rezultirati povišenjem koncentracija darunavira i ritonavira u plazmi (npr. indinavir, sistemski azoli kao što je ketokonazol i klotrimazol).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, telaprevir, fluticasone, and bosentan) is not recommended (see interaction table below).
Ne preporučuje se istodobna primjena darunavira/kobicistata sa slabim do umjerenim induktorima CYP3A (npr. efavirenz, etravirin, nevirapin, boceprevir, telaprevir, flutikazon i bosentan) (vidjeti tablicu interakcija ispod).
Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, s- mephenytoin), which may require dose adjustment/clinical monitoring.
Istodobna primjena dasabuvira s ombitasvirom/paritaprevirom/ritonavirom može smanjiti izloženost lijekovima koji se metaboliziraju putem CYP2C19 (npr. lanzoprazol, esomeprazol, s-mefentoin) radi čega može biti potrebna prilagodba doze/klinički nadzor.
Co-administration of Descovy with other medicinal products that inhibit P-gp (e.g., cobicistat, ritonavir, ciclosporin) are expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Očekuje se da će istodobna primjena lijeka Descovy s drugim lijekovima koji inhibiraju P-gp (npr. kobicistat, ritonavir, ciklosporin) povećati apsorpciju i koncentraciju tenofoviralafenamida u plazmi.
Co-administration of Descovy with St. John’s wort is not recommended.
Ne preporučuje se istodobna primjena lijeka Descovy s gospinom travom.
Co-administration of diltiazem and
Istovremena primjena diltiazema i
Co-administration of dolutegravir and other medicinal products that inhibit these enzymes may increase dolutegravir plasma concentration (see Table 1).
Istodobna primjena dolutegravira i drugih lijekova koji inhibiraju spomenute enzime može povećati koncentracije dolutegravira u plazmi (vidjeti Tablicu 1).
Co-administration of Duaklir Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Istodobna primjena Duaklir Genuaira s drugim lijekovima koji sadrže antikolinergike i/ili dugodjelujuće β2 -adrenergičke agoniste nije ispitana i ne preporučuje se.
Co-administration of efavirenz
Ne očekuje se da bi istodobna
Co-administration of efavirenz
Ne preporučuje se istodobna
Co-administration of efavirenz (enzyme inducer) based
Istodobna primjena režima utemeljenih na efavirenzu
Co-administration of efavirenz and cobicistat is expected to decrease cobicistat plasma concentrations.
Očekuje se da će istovremena primjena efavirenza i kobicistata smanjiti koncentracije kobicistata u plazmi.
Co-administration of efavirenz and elvitegravir is expected to decrease elvitegravir plasma concentrations which may result in loss of therapeutic effect and possible development of resistance.
istovremena primjena efavirenza i elvitegravira očekivano smanjuje koncentracije elvitegravira u plazmi, što može rezultirati gubitkom terapijskog učinka i mogućim razvojem rezistencije.
Co-administration of efavirenz and St. John’s wort or herbal preparations containing St. John’s wort is contraindicated.
Istodobna primjena efavirenza i gospine trave ili biljnih pripravaka koji sadrže gospinu travu je kontraindicirana.
co-administration of efavirenz with
koja je sadržavala efavirenz i ispitanika
co-administration of efavirenz with
Preporuke za istodobnu primjenu s efavirenzom
Co-administration of efavirenz with atazanavir/ritonavir is not recommended.
Ne preporučuje se istovremena primjena efavirenza s atazanovirom/ritonavirom.
Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
Istodobna primjena efavirenza s atorvastatinom, pravastatinom ili simvastatinom nije utjecala na vrijednosti AUC ni Cmax efavirenza
Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
Istovremena primjena efavirenza s atorvastatinom, pravastatinom ili simvastatinom nije imalo učinak na vrijednosti efavirenza AUC ili Cmax.
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended unless needed for dose adjustment (for example, with rifampicin).
Ne preporučuje se istodobna primjena efavirenza s tabletama koje sadrže fiksnu kombinaciju efavirenza, emtricitabina i tenofovirdizoproksilfumarata osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended unless needed for dose adjustment (for example, with rifampicin).
Ne preporučuje se istodobna primjena efavirenza s tabletama koje sadrže fiksnu kombinaciju efavirenza, emtricitabina i tenofovirdizoproksilfumarata osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended unless needed for dose adjustment (for example, with rifampicin).
Ne preporučuje se istodobna primjena efavirenza s tabletama koje sadrže fiksnu kombinaciju efavirenza, emtricitabina i tenofovirdizoproksilfumarata,osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
Co-administration of efavirenz with the fixed-combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended, unless needed for dose adjustment (for example, with rifampicin).
Ne preporučuje se istodobna primjena efavirenza i fiksnih kombiniranih tableta koje sadrže efavirenz, emtricitabin i tenofovir disoproksil fumarat, osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
Co-administration of eltrombopag with lopinavir/ritonavir (LPV/RTV) may cause a decrease in the concentration of eltrombopag.
Istodobna primjena eltrombopaga s lopinavirom/ritonavirom (LPV/RTV) može uzrokovati smanjenje koncentracije eltrombopaga.
Co-administration of eluxadoline with cyclosporine (an OATP1B1 inhibitor) increased eluxadoline exposure by approximately 5-fold (see sections 4.3 and 4.5).
Istodobna primjena eluksadolina s ciklosporinom (inhibitorom OATP1B1) povećala je izloženost eluksadolinu za približno 5 puta (vidjeti dijelove 4.3 i 4.5).
Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate have not been studied and, therefore, should be avoided.
Istovremena primjena elvitegravira i oralnih kontraceptiva koji sadrže druge progestagene umjesto norgestimata, nije ispitana te se stoga mora izbjegavati.
Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.
Istodobna primjena emtricitabina s lijekovima koji se eliminiraju aktivnom tubularnom sekrecijom moţe povećati koncentracije emtricitabina i/ili istodobno primijenjenog lijeka.
Co-administration of Emtricitabine/Tenofovir disoproxil Zentiva and didanosine is not recommended (see section 4.4).
Istodobna primjena lijeka Emtricitabine/Tenofovir disoproxil Zentiva i didanozina se ne preporučuje (vidjeti dio 4.4).
Co-administration of enzalutamide (160 mg once daily) with single oral doses of sensitive CYP substrates in prostate cancer patients resulted in an 86% decrease in the AUC of midazolam (CYP3A4 substrate), a 56% decrease in the AUC of S-warfarin (CYP2C9 substrate), and a 70% decrease in the AUC of omeprazole (CYP2C19 substrate).
Istovremena primjena enzalutamida (160 mg jedanput na dan) uz jednokratne peroralne doze osjetljivih supstrata CYP u bolesnika s karcinomom prostate dovela je do smanjenja AUC midazolama (supstrata CYP3A4) za 86%, smanjenje AUC S-varfarina (supstrata CYP2C9) za 56% i smanjenja AUC omeprazola (supstrata CYP2C19) za 70%.
Co-administration of Epclusa with efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is expected to decrease the concentration of velpatasvir.
Očekuje se da će istodobna primjena lijeka Epclusa s efavirenzom/emtricitabinom/ tenofovirdizoproksilfumaratom smanjiti koncentracije velpatasvira.
Co-administration of Epclusa with rifapentine is expected to decrease the concentration of sofosbuvir and velpatasvir, leading to reduced therapeutic effect of Epclusa.
Očekuje se da će istodobna primjena lijeka Epclusa s rifapentinom smanjiti koncentraciju sofosbuvira i velpatasvira i tako dovesti do smanjenog terapijskog učinka lijeka Epclusa.
Co-administration of etravirine and cobicistat is expected to decrease cobicistat plasma concentrations.
Očekuje se da će istovremena primjena etravirina i kobicistata smanjiti koncentracije kobicistata u plazmi.
Co-administration of Eviplera and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Ne preporučuje se istovremena primjena lijeka Eviplera i didanozina, jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration of Eviplera and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil fumarate, which may increase the risk of didanosine-related adverse reactions (see section 4.5).
Istovremena primjena lijeka Eviplera i didanozina ne preporučuje se, budući da je izloženost didanozinu značajno povećana nakon istovremene primjene tenofovirdizoproksilfumarata, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration of EVOTAZ and
Istodobna primjena lijeka EVOTAZ
Co-administration of EVOTAZ and
Ne preporučuje se istodobna
Co-administration of EVOTAZ with
Ne preporučuje se istodobna
Co-administration of EVOTAZ with medicinal products that are strong inducers of CYP3A (such as carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John’s wort [Hypericum perforatum]) may result in decreased plasma concentrations of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir (see section 4.3 and Table 1).
Istodobna primjena lijeka EVOTAZ i lijekova koji su jaki induktori CYP3A (kao što su karbamazepin, fenobarbital, fenitoin, rifampicin i gospina trava [Hypericum perforatum]) može za posljedicu imati smanjene plazmatske koncentracije atazanavira i/ili kobicistata, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije na atazanavir (vidjeti dio 4.3 i Tablicu 1).
Co-administration of EVOTAZ with warfarin has the potential to produce serious and/or life- threatening bleeding due to increased warfarin plasma concentrations, and it is recommended that the INR (International Normalized Ratio) be monitored (see section 4.5).
Istodobna primjena lijeka EVOTAZ s varfarinom može uzrokovati ozbiljno i/ili po život opasno krvarenje zbog povišenih plazmatskih koncentracija varfarina i stoga se preporučuje kontrolirati INR (internacionalni normalizirani omjer) (vidjeti dio 4.5).
Co-administration of Exviera with medicinal products that are strong or moderate enzyme inducers is expected to decrease dasabuvir plasma concentrations and reduce its therapeutic effect (see section
Pri istodobnoj primjeni lijeka Exviera s lijekovima koji su snažni ili umjereni induktori enzima očekuje se snižavanje koncentracije dasabuvira u plazmi i smanjenje njegovog terapijskog učinka (vidjetio dio 4.5).